MAPT and Alzheimer disease: Future longitudinal studies monitoring tau/Aβ accumulation, cSVD, BBB leakage, and CAA formation comprehensively in ante mortem cohorts should provide further clues as to how the cerebrovascular system can be targeted for therapy in VCID and AD.